Effects of Exercise Training in Patients With Chronic Heart Failure and Advanced Left Ventricular Systolic Dysfunction Receiving .BETA.-Blockers

DOI Web Site PubMed 被引用文献10件 参考文献63件
  • Nishi Isao
    Division of Cardiology, National Cerebral and Cardiovascular Center
  • Noguchi Teruo
    Division of Cardiology, National Cerebral and Cardiovascular Center
  • Iwanaga Yoshitaka
    Division of Cardiology, National Cerebral and Cardiovascular Center
  • Furuichi Shinichi
    Division of Cardiology, National Cerebral and Cardiovascular Center
  • Aihara Naohiko
    Division of Cardiology, National Cerebral and Cardiovascular Center
  • Takaki Hiroshi
    Division of Cardiology, National Cerebral and Cardiovascular Center
  • Goto Yoichi
    Division of Cardiology, National Cerebral and Cardiovascular Center

この論文をさがす

抄録

Background: It remains unclear whether patients with chronic heart failure (CHF) and advanced left ventricular (LV) dysfunction on β-blocker therapy benefit from exercise training (ET). Methods and Results: We studied 45 CHF patients with advanced LV dysfunction [ejection fraction (LVEF) <25%] and impaired exercise tolerance [normalized peak oxygen uptake (PVO2) <70%] receiving a β-blocker: 33 patients participated in a cardiac rehabilitation program with ET (ET group) and 12 did not (inactive control group). Exercise capacity, LV dimension and plasma B-type natriuretic peptide (BNP) were assessed before and after a 3-month study period. At baseline, both groups had markedly reduced LVEF (ET group 18±4% vs. Control group 18±5%, NS) and impaired exercise capacity (normalized PVO2 51±10% vs. 55±9%, NS). Although one patient in the ET group withdrew from the program due to worsening CHF, no serious cardiac events occurred during the ET sessions. After 3 months, the ET group (n=24) had significantly improved PVO2 by 16±15% (1,005±295 to 1,167±397ml/min, P<0.001), while the PVO2 of the control group was unchanged. LV end-diastolic dimension decreased in both groups to a similar extent, but plasma BNP was significantly decreased only in the ET group (432 to 214pg/ml, P<0.05). Conclusions: The data indicate that in CHF patients with advanced LV dysfunction on β-blocker therapy, ET successfully improves exercise capacity and BNP without adversely affecting LV remodeling or causing serious cardiac complications. (Circ J 2011; 75: 1649-1655)<br>

収録刊行物

  • Circulation Journal

    Circulation Journal 75 (7), 1649-1655, 2011

    一般社団法人 日本循環器学会

被引用文献 (10)*注記

もっと見る

参考文献 (63)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ